

## Call for Submissions


### ***Tumor Biology* Special Issue: “Lung Cancer Tumor Markers”**

Guest Editors:

**Prof. Stefan Holdenrieder**, Technical University Munich, Germany

**Dr. Huub van Rossum**, The Netherlands Cancer Institute Amsterdam

**Prof. Michel van den Heuvel**, Radboud University Medical Center Nijmegen,  
The Netherlands



*Tumor Biology* is pleased to announce a call for submissions for a special thematic issue on **Lung Cancer Tumor Markers**, which is scheduled for publication in October/November 2022. The submission deadline is **July 31, 2022**.

*Tumor Biology* is the official Journal of the International Society of Oncology and Biomarkers (ISOBM). It is a peer reviewed, international journal providing an open access forum for experimental and clinical cancer research. It covers all aspects of tumor markers, molecular biomarkers, tumor targeting, and mechanisms of tumor development and progression. The audience of the journal are clinical and laboratory professionals as well as scientists with interest in cancer biology and diagnosis and treatment of oncological patients.

As *Tumor Biology* is an open access journal, a regular article processing fee of EUR 1250 (or US\$ equivalent) is usually charged. For the special issue, a reduced fee of EUR 625 (or US\$ equivalent) offered.

#### **Background to the Special Issue:**

It is widely accepted that blood-based protein tumor markers mirror severity, extent and aggressiveness of lung cancer. They are often used for the diagnosis, prognosis, prediction, and monitoring of tumor disease. Clinical, biological, and laboratory knowledge that is key for accurate application and interpretation of the markers is presented by experts in the field.

During the last 10 years, there has been significant development in the field of serum and plasma protein tumor marker in lung cancer that has not received appropriate awareness. Reasons for this include lack of knowledge from a clinical and laboratory point of view, higher interest in molecular markers, and sometimes dilution by poor quality studies and retrospective character of the analyses. This also often prevents the inclusion of serum and plasma protein tumor markers in clinical guidelines.

The present special issue provides a platform for high quality articles on protein tumor markers in lung cancer. Comprehensive reviews and opinion papers by renowned authors, as well as original research articles filling the gaps of evidence will comprehensively cover the field of tumor marker diagnostics with a focus on lung cancer.

#### **Potential topics of interest include:**

- **Clinical perspective for use of lung cancer tumor markers**
- **Technologies, preanalytical, analytical, and quality aspects**
- **Use of tumor markers for screening and differential diagnosis of lung cancer**
- **Use of tumor markers for estimating prognosis in patients with lung cancer**
- **Use of tumor markers for monitoring disease course and therapy response in patients with lung cancer**
- **Use of biostatistics and algorithms for combination and modelling of tumor markers**
- **New blood- or other body fluid-based tumor markers for lung cancer**
- **Requirements for tumor marker studies to fill current gaps and achieve high evidence results**

The articles can be submitted via the *Tumor Biology* submission site <http://editorialmanager.com/tub> referenced with “Special Issue: Lung Cancer Tumor Marker” in the cover letter.

Prospective authors are encouraged to notify the issue editors of their intent to submit an article: **Prof. Stefan Holdenrieder**, [s.holdenrieder@tum.de](mailto:s.holdenrieder@tum.de), **Dr. Huub van Rossum**, [h.v.rossum@nki.nl](mailto:h.v.rossum@nki.nl), and **Prof. Michel van den Heuvel**, [michel.vandenheuvel@radboudumc.nl](mailto:michel.vandenheuvel@radboudumc.nl)